Phase 1 Head and Neck Cancer Trial, Recruiting NCT06109207 Sponsor: West China Hospital Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 1 Head and Neck Cancer Trial, Recruiting

NCT06109207
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older.
  • You have been diagnosed with a type of head and neck cancer (called HNSCC) confirmed by a lab test — but not nasopharyngeal carcinoma (a specific type of throat cancer).
  • Your cancer has been newly diagnosed and has not spread to other parts of the body.
  • A surgeon has determined that your cancer can be removed with surgery, and you are willing to have the surgery.
  • You are generally able to carry out daily activities with no more than minor limitations (confirm with trial site).
  • Your blood, liver, and kidney functions are within acceptable levels based on blood tests (confirm with trial site).
  • You have signed a form showing you agree to take part in the trial.

Who may not be able to join:

  • You have had another type of cancer, unless it was fully cured more than 5 years ago and has not come back (some exceptions may apply — confirm with trial site).
  • You have an active autoimmune disease (where your immune system attacks your own body) that requires ongoing treatment, or you have a history of a severe autoimmune condition.
  • You have a history of serious allergic reactions, especially to any ingredients in the study drug.
  • You have previously been treated with certain cancer medicines, including specific immune checkpoint drugs or targeted therapies (confirm with trial site).
  • You received a live vaccine within 4 weeks before starting the trial, or plan to during the study.
  • You had major surgery or a serious injury within 4 weeks before starting the trial.
  • You still have significant side effects from a previous cancer treatment that have not resolved.
  • You have serious heart problems, such as significant heart failure, irregular heartbeat, or a heart pumping function below 50%.
  • You have certain lung conditions, including lung inflammation, active tuberculosis, or a history of tuberculosis that was not successfully treated.
  • You have an overactive thyroid or a structural thyroid disease.
  • You have an active infection or unexplained fever around the time of starting the trial.
  • You have active hepatitis B or C, a known positive HIV test, or AIDS.
  • You have a diagnosed neurological or psychiatric condition.
  • You have a history of drug or alcohol abuse.
  • You are pregnant, breastfeeding, planning to become pregnant, or unwilling to use appropriate contraception during the study and for 3 months after it ends.
  • You have taken part in another clinical trial or received an experimental drug within the past 4 weeks.
  • The trial doctors have identified any other reason that makes you unsuitable for the trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jin Zhou, MD.,PhD., West China Hospital

Phone: +8613880626596

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
West China Hospital
Registry
ClinicalTrials.gov
Start date
31 October 2023
Est. completion
31 October 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Safety of combination camrelizumab and dalpiciclib as assessed by number of participants who experience adverse events; Feasibility of combination camrelizumab and dalpiciclib as assessed by number of participants who experience adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov